Charterhouse Capital Partners

Founded in 1934,[3] Charterhouse Capital Partners is one of Europe’s oldest private equity firms.[4] The firm's predecessors, then a division of Charterhouse Bank, began raising third party equity in 1976.[3] In June 2001, the firm's management completed a management buyout from HSBC to become an independent investment firm.[5]

In 2009, Charterhouse acquired Wood Mackenzie, selling its stake to Hellman & Friedman in 2012.[6]

In 2010, the company acquired Deb Group, a skincare product group, and sold its stake in 2015 to SC Johnson, reportedly earning a return of over 2.5x.[7]

In 2010, they acquired Card Factory, exiting its stake in 2015.[8]

In 2011, the company acquired ERM, and in 2015, sold its stake to Omers in a deal valued at $1.7 billion.[9]

In 2011, they acquired Webhelp, selling the company to KKR in 2015.[10]

In 2013, Charterhouse acquired Doc Generici, an Italian pharmaceutical business, selling in 2016 to CVC Capital Partners.[11]

In 2013, the company acquired Armacell in a €520 million deal and, in 2015, sold to a Blackstone led partnership in a deal valued at €960 million.[12]

In 2016, the company acquired Cooper, a provider of generalist over-the-counter (OTC) self-care pharmaceuticals, and in March 2021 sold a majority stake to CVC.[13]

In 2017, the company acquired a majority stake in SERB, a Brussels headquartered specialty pharmaceuticals company.[14]

In 2018, they acquired a majority stake in Siaci Saint Honore (SSH), a B2B insurance broker, and sold in July 2021 to a consortium led by Burrus Group.[15]

In 2015, Charterhouse acquired Mirion Technologies, a radiation detection provider, for $750 million, and in June 2021, Mirion announced it would go public after merging with a Goldman Sachs backed SPAC in a deal valued at $2.6 billion.[16]

• Company website